Trust Point Inc. Cuts Position in Repligen Corporation (NASDAQ:RGEN)

Trust Point Inc. decreased its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 35.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,756 shares of the biotechnology company's stock after selling 2,030 shares during the quarter. Trust Point Inc.'s holdings in Repligen were worth $478,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in RGEN. Price T Rowe Associates Inc. MD lifted its stake in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after purchasing an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after purchasing an additional 594,189 shares during the last quarter. Groupama Asset Managment lifted its stake in Repligen by 12,321.0% during the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after purchasing an additional 400,680 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Repligen during the fourth quarter worth approximately $53,428,000. Finally, Raymond James Financial Inc. purchased a new stake in Repligen during the fourth quarter worth approximately $52,492,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on RGEN shares. Wall Street Zen upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Thursday, May 8th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a research note on Tuesday, April 29th. Evercore ISI started coverage on Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target on the stock. JPMorgan Chase & Co. cut their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Repligen has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Repligen Stock Performance

RGEN traded down $3.47 during trading on Wednesday, hitting $117.54. The stock had a trading volume of 1,449,380 shares, compared to its average volume of 738,146. The firm has a market capitalization of $6.60 billion, a P/E ratio of -261.20, a PEG ratio of 3.46 and a beta of 1.10. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen Corporation has a twelve month low of $102.97 and a twelve month high of $182.52. The company's 50-day moving average price is $128.74 and its 200 day moving average price is $142.37.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The business's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 earnings per share. On average, equities research analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.